Top 100 medical and healthcare startups in USA
Nov 20, 2025
Like
19
1
Funding: $75M
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
2
Funding: $100M
Azalea Therapeutics is a biotech company co-founded by Nobel laureate and CRISPR co-creator Jennifer Doudna to develop a revolutionary cancer vaccine - a single injection that reprograms a patient's T cells directly within the body (in vivo). The technology combines virus-like particles (EDVs) for precise delivery of the CRISPR editor and adeno-associated viruses, which allow genes to be inserted into precisely defined sections of DNA. The combination of these technologies enables a single injection that modifies T cells while preserving their natural behavior. The company is also exploring the possibility of applying the technology to hematopoietic stem cells and B cells. Azalea stands out from its competitors thanks to its unique ability to precisely program gene placement in immune cells.
Azalea Therapeutics is a biotech company co-founded by Nobel laureate and CRISPR co-creator Jennifer Doudna to develop a revolutionary cancer vaccine - a single injection that reprograms a patient's T cells directly within the body (in vivo). The technology combines virus-like particles (EDVs) for precise delivery of the CRISPR editor and adeno-associated viruses, which allow genes to be inserted into precisely defined sections of DNA. The combination of these technologies enables a single injection that modifies T cells while preserving their natural behavior. The company is also exploring the possibility of applying the technology to hematopoietic stem cells and B cells. Azalea stands out from its competitors thanks to its unique ability to precisely program gene placement in immune cells.
3
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
4
Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
5
Funding: $3.4B
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
6
Funding: $3B
Altos Labs is working on biological reprogramming technology to essentially prolong human life
Altos Labs is working on biological reprogramming technology to essentially prolong human life
7
Funding: $2.8B
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
8
Funding: $2.4B
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
9
Funding: $2.4B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
10
Funding: $2.3B
Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
11
Funding: $2.3B
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
12
Funding: $2.3B
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
13
Funding: $2B
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
14
Funding: $2B
Oscar is a health insurance company that employs technology, design, and data to humanize health care.
Oscar is a health insurance company that employs technology, design, and data to humanize health care.
15
Funding: $2B
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
16
Funding: $1.9B
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
17
Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
18
Funding: $1.9B
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
19
Funding: $1.6B
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
